Stock 4503 ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Astellas Pharma Inc.

Astellas Pharma Inc. Stock price

Equities

4503

JP3942400007

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 01:00:00 2023-12-07 am EST 		Intraday chart for Astellas Pharma Inc. 5-day change 1st Jan Change
1,787 JPY -1.24% -0.06% -10.94%
03:00pm US sets policy to seize government-funded drug patents if price deemed too high RE
Dec. 01 Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer CI

Financials

Sales 2024 * 1,559B 10.77B Sales 2025 * 1,674B 11.56B Capitalization 3,244B 22.4B
Net income 2024 * 140B 968M Net income 2025 * 199B 1.37B EV / Sales 2024 *
2,37x
Net Debt 2024 * 449B 3.1B Net Debt 2025 * 317B 2.19B EV / Sales 2025 *
2,13x
P/E ratio 2024 *
23,7x
P/E ratio 2025 *
16,2x
Employees 14,484
Yield 2024 *
3,87%
Yield 2025 *
4,16%
Free-Float 98.82%
More Fundamentals * Assessed data

Chart Astellas Pharma Inc.

Dynamic Chart

Latest news about Astellas Pharma Inc.

US sets policy to seize government-funded drug patents if price deemed too high RE
Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer CI
Astellas, Seagen : Cancer Treatment Padcev Supplemental Biologics License Application Gets FDA Priority Review DJ
Merck Says FDA Grants Priority Review to Application for Keytruda Plus Padcev for Urothelial Cancer Treatment MT
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy CI
China arranges for Japanese officials to visit detained Japanese citizen RE
China arranges for Japanese officials to visit detained Japanese citizen -China foreign ministry RE
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings MT
Less than 30% of Japanese firms plan China expansion - survey RE
Shopper360 Names Financial Controller MT
Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday as Treasury Yields Decline MT
Astellas Pharma Acquires Propella Therapeutics in $175M Deal, Gains Access to Innovative Oncology Drugs MT
Pfizer: FDA approval for cancer CF
Pfizer, Astellas Say Xtandi Receives FDA's Approval of Supplemental Application for Treatment of Prostate Cancer MT
Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting CI
More news

Analyst Recommendations on Astellas Pharma Inc.

Jefferies Upgrades Astellas Pharma to Buy From Hold, Keeps Price Target at 2,400 Yen MT
Jefferies Adjusts Astellas Pharma's Price Target to 2,400 Yen From 2,300 Yen, Keeps at Buy MT
Jefferies Adjusts Astella Pharma’s Price Target to 2,300 Yen From 2,200 Yen, Keeps at Buy MT
Jefferies Upgrades Astellas Pharma to Buy From Hold, Adjusts Price Target to 2,200 Yen From 2,100 Yen MT
More recommendations

Press releases Astellas Pharma Inc.

Outgoing Japan envoy regrets not being able to rescue detained man AQ
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies AQ
Astellas Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy AQ
Japan envoy meets citizen detained in China over spying for 1st time AQ
Astellas Pharma Inc. - University of Tsukuba and Astellas Confirm a Strategic Partnership AQ
More press releases

News in other languages on Astellas Pharma Inc.

Pfizer : approbation de la FDA pour un cancer
China y Japón reafirman su "relación estratégica" en unas conversaciones inusuales entre líderes
MÄRKTE ASIEN/Uneinheitlich - Tokio und Hongkong sehr schwach
MÄRKTE ASIEN/Tokio und Hongkong schwach - Evergrande wieder ausgesetzt
Merck : données positives dans le cancer urothélial
More news

Quotes and Performance

1 day-1.24%
1 week-0.58%
Current month-0.58%
1 month+0.22%
3 months-19.05%
6 months-20.93%
Current year-10.94%
More quotes

Highs and lows

1 week
1 777.00
Extreme 1777
1 814.00
1 month
1 748.00
Extreme 1748
1 839.50
Current year
1 748.00
Extreme 1748
2 360.50
1 year
1 748.00
Extreme 1748
2 360.50
3 years
1 470.00
Extreme 1470
2 360.50
5 years
1 356.00
Extreme 1356
2 360.50
10 years
1 062.00
Extreme 1062
2 360.50
More quotes

Managers and Directors - Astellas Pharma Inc.

Managers TitleAgeSince
Naoki Okamura CEO
 Chief Executive Officer 61 1986
Kenji Yasukawa CHM
 Chairman 63 1986
Minoru Kikuoka DFI
 Director of Finance/CFO 61 2022
Members of the board TitleAgeSince
Takashi Tanaka BRD
 Director/Board Member 66 2021
Mamoru Sekiyama BRD
 Director/Board Member 74 2017
Naoki Okamura CEO
 Chief Executive Officer 61 1986
More insiders

ETFs positioned on Astellas Pharma Inc.

Name Weight AuM 1st Jan change Investor Rating
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY ETF Nomura NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY
11.47% 7 M€ +2.67%
AMUNDI INDEX MSCI JAPAN SRI PAB - UCITS ETF DR - GBP HEDGED (C) ETF AMUNDI INDEX MSCI JAPAN SRI PAB - UCITS ETF DR - GBP HEDGED (C)
4.85% 11 M€ +23.50%
AMUNDI INDEX MSCI JAPAN SRI PAB - UCITS ETF DR - USD HEDGED (C) ETF AMUNDI INDEX MSCI JAPAN SRI PAB - UCITS ETF DR - USD HEDGED (C)
4.85% 10 M€ +24.54%
AMUNDI INDEX MSCI JAPAN SRI PAB - UCITS ETF DR - CHF HEDGED (C) ETF AMUNDI INDEX MSCI JAPAN SRI PAB - UCITS ETF DR - CHF HEDGED (C)
4.85% 4 M€ -.--%
AMUNDI INDEX MSCI JAPAN SRI PAB - UCITS ETF DR - EUR HEDGED (D) ETF AMUNDI INDEX MSCI JAPAN SRI PAB - UCITS ETF DR - EUR HEDGED (D)
4.85% 1 M€ +21.66% -
More ETFs positioned on Astellas Pharma Inc.

Quotes

Date Price Change Volume
23-12-07 1,787 -1.24% 6 486 200
23-12-06 1,809.5 +1.06% 5,238,500
23-12-05 1,790.5 -0.17% 5,357,400
23-12-04 1,793.5 -0.72% 5,674,500
23-12-01 1,806.5 +0.50% 4,955,600

Delayed Quote Japan Exchange, December 07, 2023 at 01:00 am EST

More quotes

Company Profile

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Sector
Pharmaceuticals
Calendar
2024-01-30 - Q3 2023 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Astellas Pharma Inc.

Trading Rating :
Investor Rating :
ESG Refinitiv :
A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
1,809.5JPY
Average target price
2,610JPY
Spread / Average Target
+44.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ASTELLAS PHARMA INC. Stock Astellas Pharma Inc.
-10.94% 22 027 M $
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+61.07% 530 B $
NOVO NORDISK A/S Stock Novo Nordisk A/S
+43.20% 438 B $
JOHNSON & JOHNSON Stock Johnson & Johnson
-11.34% 377 B $
MERCK & CO., INC. Stock Merck & Co., Inc.
-4.79% 268 B $
ABBVIE INC. Stock AbbVie Inc.
-9.42% 258 B $
ROCHE HOLDING AG Stock Roche Holding AG
-13.34% 230 B $
NOVARTIS AG Stock Novartis AG
+0.55% 200 B $
ASTRAZENECA PLC Stock AstraZeneca PLC
-9.56% 198 B $
PFIZER, INC. Stock Pfizer, Inc.
-43.81% 163 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Astellas Pharma Inc. - Japan Exchange
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer